Become a MemberHomeJoin Mailing ListContact Us

Accreditation

 

CME ACCREDITATION

This activity is planned for AMA PRA Category 27.5 Credit(s)™.

 

HOW TO OBTAIN YOUR CME CERTIFICATE

Please complete the following two forms and return to IASLC CME Consultant Deb Whippen at deb.whippen@iaslc-cme.org. Entering your name on the signature line on the CME Certificate coupled with your email does constitute an electronic signature.

 

  1. Conference Evaluation Form (pdf) - click here to download
  2. CME Certificate Form (pdf) - click here to download

Please return both completed forms to Deb Whippen at deb.whippen@iaslc-cme.org.

 

DISCLOSURE INFORMATION

All speakers MUST include a slide with their disclosure information in their final presentation slides.

 

Click here to download the Faculty Disclosure Summary (pdf) >>

 

 

PROGRAM HIGHLIGHTS

At the 15th World Conference on Lung Cancer, the learning objectives are:

 

• Recommend effective tobacco control and smoking cessation

• Identify effective global lung cancer prevention strategies
• Define risk stratification for screening and early detection
• Identify optimal biopsy and molecular testing strategies to support individualized care
• Apply cost-effective imaging for diagnosis, staging and follow-up
• Describe best practice multi-disciplinary management and identify barriers to its implementation
• Identify emerging technologies relevant to recent advances in treatment for lung cancer
• Define optimal symptom relief and palliation strategies for thoracic cancers
• Practice survivorship and support strategies

 

 

GOALS

Lung Cancer is the leading cause of death worldwide[1]. Despite intensive research efforts to discover more effective treatment regimens, the survival rates for lung cancer remain low[2]. However, data from lung cancer research continue to emerge, with the identification of genetic mutations and the development of molecularly targeted agents that can help usher in the era of personalized lung cancer treatment[3]. The World Conference on Lung Cancer provides a forum for the dissemination of the latest research findings to help physicians and researchers in lung cancer remain current on the optimum treatment approaches for individuals with lung cancer, as well as on issues related to prevention, early detection, imaging, staging according to the new IASLC staging system, therapy, and palliative care.[4] The World Conference also addresses the importance of tobacco control in reducing the morbidity and mortality associated with lung cancer.

 

[1] Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM.GLOBOCAN 2008 v1.2, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10 [Internet] Lyon, France: International Agency for Research on Cancer, 2010. Available from: http://globocan.iarc.fr. Accessed May 2011.

[2] U.S. National Institutes of Health. National Cancer Institute: SEER Cancer Statistics Review, 1973-2008.

[3] Cagle PT, Chirieac LR: Advances in treatment of lung cancer with targeted therapy. Arch Pathol Lab Med. 2012 May;136(5):504-9.

[4] Senan S, Postmus PE. Reflections on the 14th World Conference on Lung Cancer: A European Perspective. Oncologist. 2012 Feb 21

 

 

CAN COMMERCIAL EMPLOYEES BE LISTED AS CO-AUTHORS FOR ABSTRACTS?

Yes, commercial employees can be listed as co-authors.

 

 

CAN COMMERCIAL EMPLOYEES PRESENT ABSTRACTS ABOUT THEIR COMPANY'S PRODUCT(S)?

No, except in rare circumstances, this is not permitted. Under rare exceptions, a commercial employee who possesses unique expertise not available otherwise may be permitted to present. This exception requires a compelling justification and prior written approval by the WCLC 2013 Conference Presidents. Special disclosures and appropriate monitoring by WCLC 2013 program leaders will be required.

 

 

PRESENTATION CONTENT - FACULTY RESPONSIBILITY

Presenters warrant that nothing in their presentation is libelous or will infringe the rights of any third party. Presenters also warrant that for any third party materials incorporated into their presentation, they have obtained all necessary permission from the copyright owner of such materials. Upon request Presenters agree to furnish copies of said permission(s) to IASLC. The Presenter is responsible for all fees, royalties, and other charges for the use of such materials. The Presenter shall indemnify IASLC for all damages, costs and expenses, including attorney's fees, incurred by IASLC as a a result of a violation of this paragraph.

 

CME must give a balanced view of therapeutic options. Use of generic drug names contributes to impartiality. Also, if your CME educational materials or content includes trade names then trade names from several companies should be used where available, not just trade names from a single company.

 

UNLABELED USAGE STATEMENT

The information presented at the World Conference on Lung Cancer is that of the contributing faculty and does not necessarily represent the views of the International Association for the Study of Lung Cancer and/or any named commercial entity providing financial support. Specific therapies discussed may not be approved and/or specified for use as indicated by the faculty presenters. Therefore, before prescribing any medication, please review the complete prescribing information, including indications, contraindications, warnings, precautions, and adverse effects.

 

Some drugs or medical devices demonstrated have not been cleared by the FDA or have been cleared by the FDA for specific purposes only. The FDA has stated that it is the responsibility of the physician to determine the FDA clearance status of each drug or medical devices he or she wishes to use in clinical practice.

 

"Off lable" uses of a drug or medical device may be described in CME activities so long as the "off label" use of the drug or medical device is also specifically disclosed (i.e. it must be disclosed that the FDA has not cleared the drug or device for the described purpose). Any drug or medical devise is being used "off lable" if the described use is not set forth on the product's approval label.

 

WHO SHOULD ATTEND?

The 15th World Conference on Lung Cancer will be one of the largest international gatherings of clinicians and scientists in the field of lung cancer and thoracic malignancies. Those interested in all aspects of lung cancer including surgeons, medical oncologists, radiation oncologists, pulmonologists, radiologists, pathologists, epidemiologists, basic research scientists are encouraged to attend this conference. Also, the Conference will continue implementing special sessions for nurses, allied health professional and advocacy members.

 

 

OFFICIAL LANGUAGE

The official language of the 15th World Conference on Lung Cancer is English.